文献速递冠心病外科

CABG术前替格瑞洛或氯吡格雷停药时间与围术期出血的关系

Bleeding in Patients Treated With Ticagrelor or Clopidogrel Before Coronary Artery Bypass Grafting.
PubMed 文献 · Ann Thorac Surg · 2019-03-19

基于E-CABG前瞻性多中心注册研究,纳入2311例术前服用替格瑞洛或氯吡格雷并接受单纯初次CABG的患者,按停药时间分层分析围术期出血。倾向评分匹配后,替格瑞洛停药0-2天较3天严重出血发生率更高(16.0% vs 2.7%,p=0.003);氯吡格雷停药0-3天较4-5天更高(15.6% vs 8.3%,p=0.031)。建议非急诊CABG在替格瑞洛停药至少3天、氯吡格雷停药至少4天后进行。

要点

  • 替格瑞洛停药0-2天行CABG严重出血风险显著高于停药3天。
  • 氯吡格雷停药0-3天行CABG严重出血风险显著高于停药4-5天。
  • 非急诊CABG应分别推迟至替格瑞洛停药3天后、氯吡格雷停药4天后。

核心结论

  • 术前服用替格瑞洛2天内或氯吡格雷3天内行CABG会增加严重出血发生率。
  • 建议非急诊CABG在替格瑞洛停药至少3天、氯吡格雷停药至少4天后实施。

研究设计与样本

  • 基于前瞻性欧洲多中心E-CABG注册研究,纳入术前服用替格瑞洛或氯吡格雷并接受单纯初次CABG的患者共2311例。
  • 其中氯吡格雷组1293例(55.9%),替格瑞洛组1018例(44.1%)。
  • 采用倾向评分匹配校正术前及围术期协变量差异。

主要发现

  • 匹配队列中,替格瑞洛停药0-2天较停药3天行CABG的严重或大量出血发生率更高(16.0% vs 2.7%,p=0.003)。
  • 匹配队列中,氯吡格雷停药0-3天较停药4-5天行CABG的严重或大量出血发生率更高(15.6% vs 8.3%,p=0.031)。
  • 氯吡格雷平均停药至手术时间为4.5±3.2天,替格瑞洛为4.9±3.0天。

关键数值与推荐

  • 主要结局采用围术期出血通用定义(Universal Definition of Perioperative Bleeding)评估严重或大量出血。
  • 次要结局包括另外四种主要出血定义。

临床怎么用

  • 非急诊CABG患者应规划替格瑞洛停药至少3天、氯吡格雷停药至少4天后再手术。
  • 术前需关注P2Y12抑制剂停药时间,以评估围术期严重出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated perioperative bleeding after coronary artery bypass grafting (CABG) in patients preoperatively treated with ticagrelor or clopidogrel, stratified by discontinuation of these P2Y12 inhibitors. METHODS: All patients from the prospective, European Multicenter Registry on Coronary Artery Bypass Grafting (E-CABG) treated with ticagrelor or clopidogrel undergoing isolated primary CABG were eligible. The primary outcome measure was severe or massive bleeding defined according to the Universal Definition of Perioperative Bleeding, stratified by P2Y12 inhibitor discontinuation. Secondary outcome measures included four additional definitions of major bleeding. Propensity score matching was performed to adjust for differences in preoperative and perioperative covariates. RESULTS: Of 2,311 patients who were included, 1,293 (55.9%) received clopidogrel and 1,018 (44.1%) ticagrelor preoperatively. Mean time between discontinuation and the operation was 4.5 ± 3.2 days for clopidogrel and 4.9 ± 3.0 days for ticagrelor. In the propensity score-matched cohort, ticagrelor-treated patients had a higher incidence of major bleeding according to Universal Definition of Perioperative Bleeding when ticagrelor was discontinued 0 to 2 days compared with 3 days before the operation (16.0% vs 2.7%, p = 0.003). Clopidogrel-treated patients had a higher incidence of major bleeding according to the Universal Definition of Perioperative Bleeding when clopidogrel was discontinued 0 to 3 days compared with 4 to 5 days before the operation (15.6% vs 8.3%, p = 0.031). CONCLUSIONS: In patients receiving ticagrelor 2 days before CABG and in those receiving clopidogrel 3 days before CABG, there was an increased rate of severe bleeding. Postponing nonemergent CABG for at least 3 days after discontinuation of ticagrelor and 4 days after clopidogrel should be considered.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Holm M, Biancari F, Khodabandeh S, et al. Bleeding in Patients Treated With Ticagrelor or Clopidogrel Before Coronary Artery Bypass Grafting. Ann Thorac Surg. 2019. PMID: 30898561. doi:10.1016/j.athoracsur.2019.01.086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。